BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:30 PM
 | 
Apr 29, 2008
 |  BC Extra  |  Top Story

Rituxan misses lupus endpoints

Genentech (NYSE:DNA) and Biogen Idec (NASDAQ:BIIB) said Rituxan rituximab missed the primary and all secondary endpoints vs. placebo in a Phase II/III trial in 257 patients with moderate-to-severe systemic lupus...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >